ABSTRACT
The curative properties of garlic in medicine have been known for a long time. However, it was only in the last three decades when garlic properties were seriously investigated confirming its potential as therapeutic medicine. The aim of this study was to measure the MIC of aqueous and methanolic extracts of garlic and to compare them with ketoconazole as positive control. In this laboratory study, the fresh smelly bulb of garlic was cleaned, skinned dryad and powdered. Garlic powder was solved in 80% methanol and distilled water. This yellow solution remained in the lab for 4 days. After that the stimmed, filtered and concentrated solution was kept remained inside the pipet in oven for 48h in 50[degree]C to make dry extract. Then methanol and aqueous dilutions [0.625 mg/ml, 1.25 mg/d 2.5 mg/ml, 5 mg/ml, 10mg/ml and 20 mg/ml] were prepared separately from 200mg powder of the concentrated extracts of garlic. Three strains of dermatophytes were cultured on the media which contained different dilutions. This experimental study showed that the rate of the effect of the aqueous extracts of garlic on Sporothrix schenckii in the minimum dilution [0.625mghl] was 8% and in the maximum dilution [20 mg/ml] was 100%. This rate in methanol extract on the same fungus was 25% and 100% in 10mg/ml dilution, respectively. The amounts of the effects of extracts on Candida albicans were 17% in the minimum dilution and 100% in 10% dilution. The effect of this plant on Cryptococcus neoforrnans was more than our expectation, because the amount of MIC in all dilutions was close to its minimum dilution [0.625mg/ml]. As the effects of the garlic extracts were the same or even more than ketoconazole and also regarding the side effects of the synthetic drugs, the use of herbs as useful drugs are necessary
ABSTRACT
Dry cough is the most common adverse effect and limiting factor of all angiotensin converting-enzyme inhibitors [ACEIs]. Prostaglandins have been pinpointed as playing an important role in the genesis of this problem. This double blind clinical trial desinged to study the efficacy of 500 milligram [mg] of aspirin comparing with placebo in controlling Enalapril-induced cough. The subjects were 32 patients who had developed Enalapril-induced cough.They were randomized into two groups: a group of daily dose of aspirin, 500 mg and a group of placebo for a treatment period of 4 weeks. Mean of cough severity was compared between two groups before treatment and weekly, until 4 weeks. Mean of cough severity in aspirin and placebo groups before and at the end of first week of treatment did not show any significant difference. After the second, third, and fourth weeks, cough severity scores were significantly reduced in aspirin group [p<0.001]. 500mg aspirin, once daily, can suppress or abolish Enalapril-induced cough and this finding proposes alternative therapeutic approach for ACEIs-induced related cough. Dry cough is the most common adverse effect and limiting factor of all angiotensin converting-enzyme inhibitors [ACEIs]. Prostaglandins have been pinpointed as playing an important role in the genesis of this problem. This double blind clinical trial desinged to study the efficacy of 500 milligram [mg] of aspirin comparing with placebo in controlling Enalapril-induced cough. The subjects were 32 patients who had developed Enalapril-induced cough.They were randomized into two groups: a group of daily dose of aspirin, 500 mg and a group of placebo for a treatment period of 4 weeks. Mean of cough severity was compared between two groups before treatment and weekly, until 4 weeks. Mean of cough severity in aspirin and placebo groups before and at the end of first week of treatment did not show any significant difference. After the second, third, and fourth weeks, cough severity scores were significantly reduced in aspirin group [p<0.001]. 500mg aspirin, once daily, can suppress or abolish Enalapril-induced cough and this finding proposes alternative therapeutic approach for ACEIs-induced related cough